(9R,13S)-13-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazole-1-yl)phenyl]-6-oxo-1,6-dihydropyrimidine-1-yl}-3-(difluoromethyl)-9-methyl-3,4,7,15-tetraazatricyclo[12.3.1.02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-one crystal

JP2026048873A5Pending Publication Date: 2026-06-16BRISTOL MYERS SQUIBB CO +1
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
BRISTOL MYERS SQUIBB CO
Filing Date
2025-12-17
Publication Date
2026-06-16

AI Technical Summary

Technical Problem

Existing pharmaceutical formulations of Compound (I) lack a balance of desirable properties such as dissolution rate, solubility, and bioavailability, making them unpredictable and challenging to manufacture and store, and there is a need for specific polymorphic crystalline forms to address these issues.

Method used

The development of crystalline forms A, B, C, D, E, F, G, H, and J of Compound (I), characterized by unique PXRD, IR, DSC, and TGA patterns, which provide a balance of stability, solubility, and bioavailability, suitable for oral administration.

Benefits of technology

These crystalline forms enhance the stability, solubility, and bioavailability of Compound (I), ensuring consistent and effective pharmaceutical compositions for treating thromboembolic disorders.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2026048873000001
    Figure 2026048873000001
  • Figure 2026048873000002
    Figure 2026048873000002
  • Figure 2026048873000003
    Figure 2026048873000003
Patent Text Reader

Abstract

This invention provides a crystalline form of compound (I), which is useful as an antithrombotic agent in the treatment of cardiovascular diseases. [Solution] Compound (I) selected from crystal A, crystal B, crystal C, crystal D, crystal E, crystal F, crystal G, crystal H, crystal I, and crystal J: JPEG2026048873000032.jpg4657 (I) A crystalline form of this is provided.
Need to check novelty before this filing date? Find Prior Art